IMGN - ImmunoGen, Inc.
| Previous Close | 10.24 |
| Open | 10.20 |
| Bid | 10.13 x 1000 |
| Ask | 10.40 x 700 |
| Day's Range | 10.01 - 10.39 |
| 52 Week Range | 3.73 - 13.41 |
| Volume | 1,728,413 |
| Avg. Volume | 3,361,382 |
| Market Cap | 1.364B |
| Beta | 2.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.98 |
| Earnings Date | Apr 27, 2017 - May 1, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.14 |
- Business Wire•2 days ago
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
- Zacks•4 days ago
Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?
Investors in ImmunoGen (IMGN) need to pay close attention to the stock based on moves in the options market lately.
- Zacks•20 days ago
Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
- Benzinga•23 days ago
The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences
Biotech stocks continued to be in the red this week, with the losses worse than what the broader market suffered. Here's a list of key events associated with biotech stocks one needs to focus on, in the ...
- Motley Fool•25 days ago
What Knocked ImmunoGen, Inc. Down 15% on Tuesday?
Investors were generally pleased with a data drop over the weekend, but it wasn't enough to keep ImmunoGen from tanking for no apparent reason on Tuesday.
- Zacks•26 days ago
ImmunoGen (IMGN) Jumps: Stock Rises 7%
ImmunoGen (IMGN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Business Wire•29 days ago
ImmunoGen Presents Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab at the Society of Gynecologic Oncology Annual Meeting
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy pembrolizumab in patients with platinum-resistant epithelial ovarian cancer .
- Zacks•last month
Is the Options Market Predicting a Spike in ImmunoGen (IMGN) Stock?
Investors in ImmunoGen (IMGN) need to pay close attention to the stock based on moves in the options market lately.
- Benzinga•last month
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
The volatile nature of biotech stocks is evident from the wild swings they experience in the wake of catalytic events, which in fact present profit-making opportunities for an astute investor. This week ...
- Business Wire•last month
ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research Annual Meeting to be held from April 14-18, 2018 in Chicago.
- MarketWatch•last month
Harry Boxer’s six stocks to watch, including two short-sale candidates
In focus: Immunogen, Kopin, Mindbody, Nutanix, Overstock.com and Dave & Buster’s.
- Motley Fool•2 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
These biotechs have promising pipeline candidates -- but can their sizzling stock momentum continue?
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Carbo Ceramics, Consolidated Communications, Catalyst Pharmaceuticals, Office Depot, ImmunoGen, and Cedar Realty Trust — What Drives Growth in Today's Competitive Landscape
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carbo ...
- Zacks•2 months ago
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
ImmunoGen (IMGN) advances with lead ovarian cancer candidate, mirvetuximab soravtansine. Moreover, combo therapies with the candidate for the indication are underway.
- Motley Fool•2 months ago
ImmunoGen Moves One Foot Forward
One step at a time is the only way to complete the marathon of drug development.
- Motley Fool•2 months ago
What's Behind ImmunoGen Inc.'s Brief Dip on Tuesday?
It looks like another day of meaningless volatility for this biotech stock.
- Motley Fool•2 months ago
Why ImmunoGen Jumped Higher Today
Investors are jumping back into the biotech for no apparent reason.
- Zacks•2 months ago
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow
ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of IMGN earnings conference call or presentation 9-Feb-18 1:00pm GMT
Q4 2017 ImmunoGen Inc Earnings Call
- Zacks•2 months ago
ImmunoGen (IMGN) Q4 Loss Wider, Revenues Rise Y/Y
ImmunoGen (IMGN) posted wider-than-expected loss in the fourth quarter of 2017. Revenues almost doubled year-over-year.
- Simply Wall St.•2 months ago
Investors Are Undervaluing ImmunoGen Inc (NASDAQ:IMGN) By 44.20%, Here Is My Intrinsic Value Calculation
In this article I am going to calculate the intrinsic value of ImmunoGen Inc (NASDAQ:IMGN) using the discounted cash flows (DCF) model. If you want to learn more about thisRead More...
- Associated Press•2 months ago
ImmunoGen reports 4Q loss
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 11 cents. Losses, adjusted for non-recurring costs, came to 10 cents per share. The results missed Wall Street expectations. ...
- Business Wire•2 months ago
ImmunoGen Reports Pipeline Progress and 2017 Operating Results
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today reviewed recent highlights and operating results for the quarter and year ended December 31, 2017.
- Zacks•2 months ago
Is a Surprise Coming for ImmunoGen (IMGN) This Earnings Season?
ImmunoGen (IMGN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
- CNBC Videos•last month
Cramer's lightning round: Investing in Disney requires pa...
Jim Cramer shares his take on callers' favorite stocks, including an entertainment play on a slow-and-steady climb.
